Researchers from Abbvie Inc. have reported on the discovery and optimization of a series of selective tyrosine kinase 2 (TYK2) inhibitors that led to the identification of ABBV-712 as the lead compound.
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections. In cancer, the specificity of T-Therapeutics’ molecules will overcome shortcomings of immuno-oncology drugs such as checkpoint inhibitors that stimulate a response to some cancer neo-antigens but are unable to recognize cancer-specific self-antigens.
Researchers from Kyverna Therapeutics Inc. have presented data on their anti-CD19 CAR T-cell therapy, KYV-101, for the treatment of B-cell-driven autoimmune diseases.
Emergex Vaccines Holding Ltd. has signed a contract with the U.K. Department of Health and Social Care (DHSC) for almost £1.8 million (US$2.2 million) to advance a CD8 T cell-based vaccine candidate against Chikungunya virus (CHIKV).
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections.
Nonreceptor tyrosine-protein kinase TYK2 plays key roles in the signaling of pro-inflammatory molecules such as IL-23, IL-12 or type I IFN, which at the same time play key roles in several immune-mediated diseases such as atopic dermatitis and psoriasis, among others.
Scirhom GmbH has submitted a clinical trial application (CTA) for its lead candidate, SR-878, an antibody designed to target inactive rhomboid protein 2 (iRhom2) as a therapeutic strategy for numerous autoimmune disorders.
There is increasing evidence on the involvement of Toll-like receptor 7 (TLR7) in the pathogenesis of systemic lupus erythematosus (SLE). At the recent American College of Rheumatology meeting, researchers from Daiichi Sankyo Co. Ltd. presented preclinical data on DS-7011a, a TLR7 antagonist antibody with for the potential treatment of SLE.
The blowup in phase II with Aclaris Pharmaceuticals Inc.’s oral MK2 inhibitor zunsemetinib (ATI-450) for moderate to severe rheumatoid arthritis (RA) sent shares (NASDAQ:ACRS) into a tailspin and sparked Wall Street speculation about the firm’s other mid-stage prospect. Wayne, Pa.-based Aclaris’ stock ended Nov. 13 at 64 cents, down $4.11, or 86%, after investors learned that ATI-450 missed the study’s primary and secondary endpoints. Development of the candidate, which was also under phase IIa investigation in psoriatic arthritis, will be stopped.
RSS
